<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077176</url>
  </required_header>
  <id_info>
    <org_study_id>Inaktif_Rapel_Faz 3</org_study_id>
    <nct_id>NCT05077176</nct_id>
  </id_info>
  <brief_title>Phase 3 Booster Vaccination Against SARS-CoV-2</brief_title>
  <official_title>Open Label, Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination Against SARS-CoV-2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Institutes of Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Institutes of Turkey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and&#xD;
      immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a&#xD;
      maximum of 270 days after the second dose of CoronaVac vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The inactivated Booster Phase 3 study aims to determine the efficacy, safety, and&#xD;
      immunogenicity of inactivated COVID-19 vaccines in subjects with a minimum of 90 days and a&#xD;
      maximum of 270 days after the second dose of CoronaVac vaccine. For the booster dose,&#xD;
      subjects will be assigned open-label according to their preference for 2 different arms.&#xD;
&#xD;
      The booster dose vaccine arms are as follows:&#xD;
&#xD;
        -  CoronaVac&#xD;
&#xD;
        -  Turkovac&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2021</start_date>
  <completion_date type="Anticipated">October 5, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-Center Phase 3 Clinical Trial to Determine Safety, Efficacy, and Immunogenicity of Booster Vaccination (CoronaVac or TURKOVAC) Against SARS-CoV-2</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19</measure>
    <time_frame>At least 14 days after booster vaccination dose</time_frame>
    <description>Protection rates of Turkovac and CoronaVac vaccines against symptomatic COVID-19 confirmed by RT-PCR at least 14 days after booster vaccination dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)</measure>
    <time_frame>7 days and 168 days after vaccination</time_frame>
    <description>To evaluate the safety of booster dose vaccines by determining the incidence of adverse reactions and serious adverse events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To Evaluate the Immunogenicity</measure>
    <time_frame>On days 0, 28, 48, 84 and 168 after vaccination</time_frame>
    <description>To evaluate the immunogenicity of booster dose vaccines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the seropositivity rate of SARS-CoV2 specific binding antibody</measure>
    <time_frame>After booster dose 0, 28 (all subjects), 48, 84 and 168 days (50% of subjects)</time_frame>
    <description>Determination of SARS-CoV2 specific binding antibody seropositivity rate after booster dose 0, 28 (all subjects), 48, 84 and 168 days (50% of subjects)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of SARS-CoV2 Neutralizing Antibodies</measure>
    <time_frame>After booster dose 0, 28 (all subjects), 48, 84 and 168 (50% of subjects)</time_frame>
    <description>Evaluation of SARS-CoV2 neutralizing antibodies by neutralization test after booster dose 0, 28 (all subjects), 48, 84 and 168 (50% of subjects)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-Cell Evaluation</measure>
    <time_frame>On days 0, 28, 48, 84 and 168 after vaccination</time_frame>
    <description>T cell evaluation in 30 - 45 subjects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">7400</enrollment>
  <condition>COVID-19</condition>
  <condition>Sars-CoV-2 Infection</condition>
  <arm_group>
    <arm_group_label>CoronaVac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Turkovac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>600 Subunit of SARS-CoV-2 virus antigen, intramuscular injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CoronaVac</intervention_name>
    <description>One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.</description>
    <arm_group_label>CoronaVac</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Turkovac</intervention_name>
    <description>One dose vaccine will be administered to subjects who have passed at least 90 days and at most 270 days after the second dose of the first course of CoronaVac vaccine.</description>
    <arm_group_label>Turkovac</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects must meet all of the following inclusion criteria to be eligible for inclusion in&#xD;
        the study:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects willing and able to give signed informed consent to participate in study,&#xD;
&#xD;
          2. Healthy male or female aged 18 - 60 years (including both groups),&#xD;
&#xD;
          3. Subjects who were vaccinated with CoronaVac for 2 doses and who had a minimum of 90&#xD;
             days and a maximum of 270 days after the second dose,&#xD;
&#xD;
          4. Subjects with 4-6 weeks between CoronaVac 1st and 2nd dose vaccines,&#xD;
&#xD;
          5. Female subjects of childbearing potential should be willing to ensure that they or&#xD;
             their partner use effective birth control methods continuously from 1 month before and&#xD;
             up to 3 months after vaccination,&#xD;
&#xD;
          6. In the opinion of the investigator, subjects capable and willing to comply with all&#xD;
             study requirements,&#xD;
&#xD;
          7. Subjects are willing to agree to abstain from donating blood during the study.&#xD;
&#xD;
        Subjects meeting any of the following criteria will not be included in the study:&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Administration of any vaccine (registered or investigational) other than study&#xD;
             intervention within 30 days before and after each study vaccine (one week for&#xD;
             authorized seasonal flu vaccine or pneumococcal vaccine),&#xD;
&#xD;
          2. Pre-or planned use of another vaccine or product likely to affect the study (e.g.&#xD;
             adenovirus vectored vaccines, any coronavirus vaccine),&#xD;
&#xD;
          3. Known history of SARS-CoV-2 infection,&#xD;
&#xD;
          4. Pregnant and puerperant subjects (subjects who become pregnant 2 months after&#xD;
             vaccination will continue to study),&#xD;
&#xD;
          5. Subjects with fever (above 37,8°C) at the time of vaccination and/or up to 72 hours&#xD;
             before (After the acute condition has resolved, the subject can be screened again),&#xD;
&#xD;
          6. Administration of immunoglobulins and/or any blood product within 3 months prior to&#xD;
             vaccination,&#xD;
&#xD;
          7. Any confirmed or suspected immunosuppressive or immunodeficiency state; asplenia;&#xD;
             recurrent severe infections and use of immunosuppressants (less than ≤14 days) in the&#xD;
             last 6 months, excluding topical steroids or short-term oral steroids,&#xD;
&#xD;
          8. Possible history of allergic disease or reaction (e.g. to the active substance) by any&#xD;
             component of the study vaccines,&#xD;
&#xD;
          9. Any history of anaphylaxis,&#xD;
&#xD;
         10. Current cancer diagnosis or treatment (excluding basal cell carcinoma of the skin and&#xD;
             cervical carcinoma in situ),&#xD;
&#xD;
         11. History of bleeding disorder (e.g. factor deficiency, coagulopathy or platelet&#xD;
             disorder), or prior history of significant bleeding or bruising following&#xD;
             intramuscular injections or venipuncture,&#xD;
&#xD;
         12. Continued use of anticoagulants such as coumarins and related anticoagulants (i.e.&#xD;
             warfarin) or new oral anticoagulants (i.e. apixaban, rivaroxaban, dabigatran and&#xD;
             edoxaban),&#xD;
&#xD;
         13. Cerebral venous sinus thrombosis, antiphospholipid syndrome, or a history of&#xD;
             heparin-induced thrombocytopenia and thrombosis (HITT or HIT type 2),&#xD;
&#xD;
         14. Suspected or known current alcohol or drug addiction,&#xD;
&#xD;
         15. Any other significant disease, disorder or finding that could significantly increase&#xD;
             the subject's risk for participation in the study, affect the subject's ability to&#xD;
             participate in the study, or impair the interpretation of study data; severe and/or&#xD;
             uncontrolled cardiovascular disease, respiratory disease, gastrointestinal disease,&#xD;
             liver disease, kidney disease, endocrine disorder, and neurological disease&#xD;
             (mild/moderate well-controlled comorbidities are permitted),&#xD;
&#xD;
         16. History of active or previous autoimmune neurological disorders (e.g. multiple&#xD;
             sclerosis, Guillain-Barre syndrome, transverse myelitis) (Bell's palsy will not be an&#xD;
             exclusion criterion),&#xD;
&#xD;
         17. Subjects with severe renal impairment or liver failure,&#xD;
&#xD;
         18. Subjects who will undergo scheduled elective surgery during the study,&#xD;
&#xD;
         19. Subjects with a life expectancy of less than 6 months,&#xD;
&#xD;
         20. Subject who participated in another clinical trial study involving an investigational&#xD;
             product in the past 12 weeks,&#xD;
&#xD;
         21. In case of clinical necessity, a COVID-19 PCR (polymerase chain reaction) test will be&#xD;
             requested from the subjects, and subjects who are positive will be excluded from the&#xD;
             study,&#xD;
&#xD;
         22. Acute respiratory disease (moderate or severe illness with or without fever).&#xD;
             (Subjects may be screened again after acute condition has resolved),&#xD;
&#xD;
         23. Insufficient level of Turkish to perform the informed consent, except where briefing&#xD;
             by an independent witness can be provided and is available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bedia Dinç, Assoc. Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty Member</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bedia Dinç, Assoc. Prof.</last_name>
    <phone>+90 (312) 552 60 00</phone>
    <email>bediadinc@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>İhsan Ateş, Assoc. Prof.</last_name>
    <phone>+90 (312) 552 60 00</phone>
    <email>dr.ihsanates@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>T.R. Ministry of Health Ankara Keçiören Sanatorium Ataturk Chest Diseases and Thoracic Surgery Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <state>Turkey Region</state>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kurtuluş Aksu, Prof.</last_name>
      <phone>+90 (312) 567 70 00</phone>
      <email>kurtulusaksu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Kurtuluş Aksu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Çukurova University Faculty of Medicine, Department of Infectious Diseases</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferit Kuşçu, Assoc. Prof.</last_name>
      <phone>+90 (322) 338 60 60</phone>
      <email>feritkuscu@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ferit Kuşçu, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Ankara City Hospital, Infectious Diseases and Clinical Microbiology Clinic</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bedia Dinç, Assoc. Prof.</last_name>
      <phone>+90 (312) 552 60 00</phone>
      <email>bediadinc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Bedia Dinç, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dışkapı SUAM Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İrfan Şencan, Prof.</last_name>
      <phone>+90 (224) 295 00 00</phone>
      <email>isencanibu@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>İrfan Şencan, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Antalya Training And Research Hospital</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remziye Nur Eke, Specialist</last_name>
      <phone>+90 (242) 2494400</phone>
      <email>drnureke@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Remziye Nur Eke, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Aydın State Hospital</name>
      <address>
        <city>Aydın</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ferdi Güneş, Specialist</last_name>
      <phone>+90 (256) 213 90 02</phone>
      <email>dr.frdgns@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ferdi Güneş, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Balıkesir Atatürk City Hospital</name>
      <address>
        <city>Balıkesir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Korhan Sığ, Specialist</last_name>
      <phone>+90 (266) 460 40 00</phone>
      <email>dr_korhan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ali Korhan Sığ, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Abant Izzet Baysal University Training and Research Hospital</name>
      <address>
        <city>Bolu</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammed Emin Demirkol, Assoc. Prof.</last_name>
      <phone>0374 253 46 26</phone>
      <email>medemirkol@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Muhammed Emin Demirkol, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Bursa City Hospital</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Canan Demir, Specialist</last_name>
      <phone>+90 (224) 975 00 00</phone>
      <email>drcanandemir@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Canan Demir, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uludağ University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emin Halis Akalın, Prof.</last_name>
      <phone>+90 (224) 295 00 00</phone>
      <email>halis@uludag.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Emin Halis Akalın, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Denizli Acıpayam State Hospital</name>
      <address>
        <city>Denizli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emin Egemen Tekin, Specialist</last_name>
      <phone>+90 (258) 518 10 64</phone>
      <email>eminegementekin@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Emin Egemen Tekin, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Elazığ Fethi Sekin City Hospital</name>
      <address>
        <city>Elazığ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gülden Eser Karlıdağ, Assoc. Prof.</last_name>
      <phone>+90 (424) 238 10 00</phone>
      <email>guldeneser@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gülden Eser Karlıdağ, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erzincan Binali Yıldırım University Training and Research Hospital Traditional and Complementary Medicine Application Center - GETAT</name>
      <address>
        <city>Erzincan</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faruk Karakeçeli, Assoc. Prof.</last_name>
      <email>drfarukkarakecili@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Faruk Karakeçeli, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Erzurum Regional Training and Research Hospital</name>
      <address>
        <city>Erzurum</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sibel İba Yılmaz, Assoc. Prof.</last_name>
      <phone>+90 (442) 432 10 00</phone>
      <email>dr.syilmaz@windowslive.com</email>
    </contact>
    <investigator>
      <last_name>Sibel İba Yılmaz, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eskişehir Osmangazi University Eskişehir Osmangazi University Health, Application and Research Hospital</name>
      <address>
        <city>Eskişehir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nurettin Erben, Prof.</last_name>
      <phone>+90 (222) 239 29 79</phone>
      <email>nerben@ogu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Nurettin Erben, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Eskişehir City Hospital</name>
      <address>
        <city>Eskişehir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anıl Uçan, Specialist</last_name>
      <phone>+90 (222) 611 4000</phone>
      <email>anil-ucan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Anıl Uçan, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Dr. Ersin Arslan Training and Research Hospital</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İbrahim Halil Türkbeyler, Assoc. Prof.</last_name>
      <phone>+90 (0342) 221 07 00</phone>
      <email>ihturkbeyler@gmail.com</email>
    </contact>
    <investigator>
      <last_name>İbrahim Halil Türkbeyler, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Kartal Dr. Lütfi Kirdar City Hospital Infectious Diseases</name>
      <address>
        <city>Istanbul</city>
        <zip>34865</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayşe Batırel, Prof.</last_name>
      <phone>+90 (0216) 458 30 00</phone>
      <email>aysebatirel@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ayşe Batırel, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cerrahpaşa Faculty of Medicine, Department of Internal Medicine - Department of Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ömer Fehmi Tabak, Prof.</last_name>
      <phone>+90 (212) 414 20 00</phone>
      <email>fehmitabak@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ömer Fehmi Tabak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Başakşehir Çam ve Sakura City Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Özlem Altuntaş Aydın, Prof.</last_name>
      <phone>+90 (212) 909 60 00</phone>
      <email>ozlemaa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Özlem Altuntaş Aydın, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Istanbul Provincial Health Directorate Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital (Prof. Dr. Feriha Öz Emergency Hospital)</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fatma Yılmaz Karadağ, Assoc. Prof.</last_name>
      <phone>+90 (216) 606 50 00</phone>
      <email>dr_fatma@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Fatma Yılmaz Karadağ, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health İstanbul Şişli Hamidiye Etfal Training and Research Hospital, Clinical Microbiology Clinic</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İlyas Dökmetaş, Prof.</last_name>
      <phone>+90 (212) 373 50 00</phone>
      <email>ilyas.dokmetas@sbu.edu.tr</email>
    </contact>
    <investigator>
      <last_name>İlyas Dökmetaş, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Health Sciences İstanbul Ümraniye Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehtap Aydın, Assoc. Prof.</last_name>
      <phone>+90 (216) 650 76 76</phone>
      <email>mehtapaydin10@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mehtap Aydın, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health İzmir Katip Çelebi University Atatürk Training and Research Hospital, Infectious Diseases Clinic</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tuna Demirdal, Prof.</last_name>
      <phone>+90 (0232) 243 43 43</phone>
      <email>tunademirdal@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Tuna Demirdal, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health İzmir Provincial Health Directorate Health Sciences University Dr Suat Seren Chest Diseases And Chest Surgery Training And Research Hospital</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Özgür Batum, Specialist</last_name>
      <phone>+90 (232) 433 33 33</phone>
      <email>ozgurbat@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Özgür Batum, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health İzmir Provincial Health Directorate İzmir Health Sciences University Tepecik Training and Research Hospital, Infectious Diseases</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Şükran Köse, Prof.</last_name>
      <phone>+90 (232) 469 69 69</phone>
      <email>sukrankose@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Şükran Köse, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kahramanmaraş Sütçü İmam University Infections Diseases</name>
      <address>
        <city>Kahramanmaraş</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selma Ateş, Prof.</last_name>
      <phone>+90 (344) 300-3585</phone>
      <email>Selmaguler38@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Selam Ateş, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erciyes University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Orhan Yıldız, Prof.</last_name>
      <phone>+90 (352) 437 49 12</phone>
      <email>oyildiz@erciyes.edu.tr</email>
    </contact>
    <investigator>
      <last_name>Orhan Yıldız, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Kayseri City Training and Research Hospital, Infectious Diseases and Clinical Microbiology Department</name>
      <address>
        <city>Kayseri</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İlhami Çelik, Prof.</last_name>
      <phone>+90 (352) 315 77 00</phone>
      <email>ilhamicelik@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>İlhami Çelik, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sıla Akhan, Prof.</last_name>
      <phone>+90 (262) 303 7563</phone>
      <email>cetinakhan@yahoo.com.tr</email>
    </contact>
    <investigator>
      <last_name>Sıla Akhan, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Kocaeli Health Sciences University Derince Training And Research Hospital</name>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Selcan Arslan Özel, Specialist</last_name>
      <phone>+90 (262) 317 80 00</phone>
      <email>selcandr@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Selcan Arslan Özel, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Konya City Hospital</name>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arzu Tarakçı, Specialist</last_name>
      <phone>+90 (332) 310 50 00</phone>
      <email>aaaribas1972@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Arzu Tarakçı, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kütahya University of Health Sciences, Infectious Diseases and Clinic</name>
      <address>
        <city>Kütahya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Öznur Ak, Prof.</last_name>
      <email>akoznur@yahoo.com.tr</email>
    </contact>
    <investigator>
      <last_name>Öznur Ak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kırıkkale University Faculty of Medicine, Department of Internal Medicine</name>
      <address>
        <city>Kırıkkale</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aydın Çiftçi, Assoc. Prof.</last_name>
      <phone>+90 (850) 304 00 71</phone>
      <email>dr.aydin.71@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Aydın Çiftçi, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Malatya İnönü University Faculty of Medicine, Department of Infectious Diseases</name>
      <address>
        <city>Malatya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaşar Bayındır, Prof.</last_name>
      <phone>+90 (422) 341 06 60</phone>
      <email>yasarb44@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Yaşar Bayındır, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Manisa City Hospital</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sevil Sapmaz Karabağ, Specialist</last_name>
      <email>s.sapmazkarabag@saglik.gov.tr</email>
    </contact>
    <investigator>
      <last_name>Sevil Sapmaz Karabağ, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Mersin City Training and Research Hospital</name>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Uğuz, Specialist</last_name>
      <phone>+90 (324) 225 10 00</phone>
      <email>mustafa_uguz@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Mustafa Uğuz, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>T.R. Ministry of Health Tekirdağ Çorlu District State Hospital</name>
      <address>
        <city>Tekirdağ</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mustafa Doğan, Assoc. Prof.</last_name>
      <phone>+90 (282) 693 33 00</phone>
      <email>mustafadogaan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mustafa Doğanc, Assoc. Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Health Sciences University Kanuni Training and Research Hospital Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Trabzon</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Özlem Bayraktar Saral, Specialist</last_name>
      <phone>+90 (216) 418 96 16</phone>
      <email>lembayraktar@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Özlem Bayraktar Saral, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Van Yüzüncü Yıl University Hospital, Faculty of Medicine, Infectious Diseases and Clinical Microbiology</name>
      <address>
        <city>Van</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmut Sünnetçioğlu, Prof.</last_name>
      <phone>+90 (850) 305 65 65</phone>
      <email>mahmutsunnetci@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Mahmut Sünnetçioğlu, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Şanlıurfa Harran University Hospital</name>
      <address>
        <city>Şanlıurfa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>İclal Hocanlı, Specialist</last_name>
      <phone>+90 (414) 344 44 44</phone>
      <email>iclalhocanli2163@gmail.com</email>
    </contact>
    <investigator>
      <last_name>İclal Hocanlı, Specialist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Kumar A, Singh R, Kaur J, Pandey S, Sharma V, Thakur L, Sati S, Mani S, Asthana S, Sharma TK, Chaudhuri S, Bhattacharyya S, Kumar N. Wuhan to World: The COVID-19 Pandemic. Front Cell Infect Microbiol. 2021 Mar 30;11:596201. doi: 10.3389/fcimb.2021.596201. eCollection 2021. Review.</citation>
    <PMID>33859951</PMID>
  </reference>
  <reference>
    <citation>Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, Ramirez SI, Haupt S, Frazier A, Nakao C, Rayaprolu V, Rawlings SA, Peters B, Krammer F, Simon V, Saphire EO, Smith DM, Weiskopf D, Sette A, Crotty S. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529). pii: eabf4063. doi: 10.1126/science.abf4063. Epub 2021 Jan 6.</citation>
    <PMID>33408181</PMID>
  </reference>
  <reference>
    <citation>Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, Mascola JR, Graham BS, Lin BC, O'Dell S, Schmidt SD, Widge AT, Edara VV, Anderson EJ, Lai L, Floyd K, Rouphael NG, Zarnitsyna V, Roberts PC, Makhene M, Buchanan W, Luke CJ, Beigel JH, Jackson LA, Neuzil KM, Bennett H, Leav B, Albert J, Kunwar P; mRNA-1273 Study Group. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-2261. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.</citation>
    <PMID>33822494</PMID>
  </reference>
  <reference>
    <citation>Wu K, Werner AP, Koch M, Choi A, Narayanan E, Stewart-Jones GBE, Colpitts T, Bennett H, Boyoglu-Barnum S, Shi W, Moliva JI, Sullivan NJ, Graham BS, Carfi A, Corbett KS, Seder RA, Edwards DK. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021 Apr 15;384(15):1468-1470. doi: 10.1056/NEJMc2102179. Epub 2021 Mar 17.</citation>
    <PMID>33730471</PMID>
  </reference>
  <reference>
    <citation>Madhi SA, Izu A, Pollard AJ. ChAdOx1 nCoV-19 Vaccine Efficacy against the B.1.351 Variant. Reply. N Engl J Med. 2021 Aug 5;385(6):571-572. doi: 10.1056/NEJMc2110093. Epub 2021 Jul 21.</citation>
    <PMID>34289271</PMID>
  </reference>
  <reference>
    <citation>Pavel STI, Yetiskin H, Aydin G, Holyavkin C, Uygut MA, Dursun ZB, Celik İ, Cevik C, Ozdarendeli A. Isolation and characterization of severe acute respiratory syndrome coronavirus 2 in Turkey. PLoS One. 2020 Sep 16;15(9):e0238614. doi: 10.1371/journal.pone.0238614. eCollection 2020.</citation>
    <PMID>32936826</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 Vaccine</keyword>
  <keyword>Booster</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

